Literature DB >> 21304033

Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.

John S Esterly1, Chad L Richardson2, Noha S Eltoukhy3, Chao Qi4, Marc H Scheetz5.   

Abstract

OBJECTIVE: To summarize published data identifying known genetic mechanisms of antibiotic resistance in Acinetobacter baumannii and the correlating phenotypic expression of antibiotic resistance. DATA SOURCES: MEDLINE databases (1966-July 15, 2010) were searched to identify original reports of genetic mechanisms of antibiotic resistance in A. baumannii. DATA SYNTHESIS: Numerous genetic mechanisms of resistance to multiple classes of antibiotics are known to exist in A. baumannii, a gram-negative bacterium increasingly implicated in nosocomial infections. Mechanisms may be constitutive or acquired via plasmids, integrons, and transposons. Methods of resistance include enzymatic modification of antibiotic molecules, modification of antibiotic target sites, expression of efflux pumps, and downregulation of cell membrane porin channel expression. Resistance to β-lactams appears to be primarily caused by β-lactamase production, including extended spectrum β-lactamases (b/aTEM, blaSHV, b/aTX-M,b/aKPC), metallo-β-lactamases (blaMP, blaVIM, bla, SIM), and most commonly, oxacillinases (blaOXA). Antibiotic target site alterations confer resistance to fluoroquinolones (gyrA, parC) and aminoglycosides (arm, rmt), and to a much lesser extent, β-lactams. Efflux pumps (tet, ade, abe) contribute to resistance against β-lactams, tetracyclines, fluoroquinolones, and aminoglycosides. Finally, porin channel deletion (carO, oprD) appears to contribute to β-lactam resistance and may contribute to rarely seen polymyxin resistance. Of note, efflux pumps and porin deletions as solitary mechanisms may not render clinical resistance to A. baumannii.
CONCLUSIONS: A. baumannii possesses copious genetic resistance mechanisms. Knowledge of local genotypes and expressed phenotypes for A. baumannii may aid clinicians more than phenotypic susceptibilities reported in large epidemiologic studies.
© 2011 SAGE Publications.

Entities:  

Keywords:  Acinetobacter baumannii; antibiotics; genetic mechanisms; resistance; β-lactamases

Mesh:

Substances:

Year:  2011        PMID: 21304033     DOI: 10.1345/aph.1P084

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  12 in total

1.  Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant Acinetobacter baumannii in Egypt.

Authors:  Heba Shehta Said; Abdalbagi Basheer Benmahmod; Ramadan Hassan Ibrahim
Journal:  World J Microbiol Biotechnol       Date:  2018-12-03       Impact factor: 3.312

2.  Co-production of ESBL and AmpC β-Lactamases in Clinical Isolates of A. baumannii and A. lwoffii in a Tertiary Care Hospital From Northern India.

Authors:  Pooja Singla; Rama Sikka; Antariksh Deeep; Deep Gagneja; Uma Chaudhary
Journal:  J Clin Diagn Res       Date:  2014-04-15

Review 3.  Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside.

Authors:  Ming-Feng Lin; Chung-Yu Lan
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

4.  Local Sustained Delivery of 25-Hydroxyvitamin D3 for Production of Antimicrobial Peptides.

Authors:  Jiang Jiang; Guojun Chen; Franklin D Shuler; Chi-Hwa Wang; Jingwei Xie
Journal:  Pharm Res       Date:  2015-03-14       Impact factor: 4.200

Review 5.  Evasion of Antimicrobial Activity in Acinetobacter baumannii by Target Site Modifications: An Effective Resistance Mechanism.

Authors:  Arturo Martínez-Trejo; Juan Manuel Ruiz-Ruiz; Luis Uriel Gonzalez-Avila; Andrés Saldaña-Padilla; Cecilia Hernández-Cortez; Miguel Angel Loyola-Cruz; Juan Manuel Bello-López; Graciela Castro-Escarpulli
Journal:  Int J Mol Sci       Date:  2022-06-13       Impact factor: 6.208

6.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities.

Authors:  Chris Rowe Taitt; Tomasz A Leski; Michael G Stockelman; David W Craft; Daniel V Zurawski; Benjamin C Kirkup; Gary J Vora
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

8.  C6 Hydroxymethyl-Substituted Carbapenem MA-1-206 Inhibits the Major Acinetobacter baumannii Carbapenemase OXA-23 by Impeding Deacylation.

Authors:  Nichole K Stewart; Marta Toth; Maha A Alqurafi; Weirui Chai; Thu Q Nguyen; Pojun Quan; Mijoon Lee; John D Buynak; Clyde A Smith; Sergei B Vakulenko
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

9.  Preterm infants harbour diverse Klebsiella populations, including atypical species that encode and produce an array of antimicrobial resistance- and virulence-associated factors.

Authors:  Yuhao Chen; Thomas C Brook; Cho Zin Soe; Ian O'Neill; Cristina Alcon-Giner; Onnicha Leelastwattanagul; Sarah Phillips; Shabhonam Caim; Paul Clarke; Lindsay J Hall; Lesley Hoyles
Journal:  Microb Genom       Date:  2020-06

Review 10.  Acinetobacter baumannii Resistance: A Real Challenge for Clinicians.

Authors:  Rosalino Vázquez-López; Sandra Georgina Solano-Gálvez; Juan José Juárez Vignon-Whaley; Jorge Andrés Abello Vaamonde; Luis Andrés Padró Alonzo; Andrés Rivera Reséndiz; Mauricio Muleiro Álvarez; Eunice Nabil Vega López; Giorgio Franyuti-Kelly; Diego Abelardo Álvarez-Hernández; Valentina Moncaleano Guzmán; Jorge Ernesto Juárez Bañuelos; José Marcos Felix; Juan Antonio González Barrios; Tomás Barrientos Fortes
Journal:  Antibiotics (Basel)       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.